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TGR5, an emerging G protein-coupled receptor, was identiﬁed as a membrane receptor for bile acids. The expression of TGR5 and
its function are distinct from the previously identiﬁed nuclear bile acid receptor, farnesoid X receptor (FXR). These two bile acid
receptors complement with each other for maintaining bile acid homeostasis and mediating bile acid signaling. Both receptors are
also shown to play roles in regulating inﬂammation and glucose metabolism. An interesting ﬁnding for TGR5 is its role in energy
metabolism. The discovery of TGR5 expression in brown adipocyte tissues (BATs) and the recent demonstration of BAT in adult
human body suggest a potential approach to combat obesity by targeting TGR5 to increase thermogenesis. We summarize here the
latest ﬁnding of TGR5 research, especially its role in energy metabolism and glucose homeostasis.
1.Introduction
Bile acids (BAs) are the main products of cholesterol catab-
olism, which constitutes a major route for the elimination
of surplus cholesterol. There are four major types of BAs:
cholic acid (CA) and chenodeoxycholic acid (CDCA) are
primary BAs; deoxycholic acid (DCA) and lithocholic acid
(LCA) are secondary BAs, which are converted from primary
BAs by bacterial enzymes in the intestine [1]. BA synthesis is
restricted to hepatocytes, and there are two distinct pathways
of BA synthesis: the classic/neutral and the alternative/acidic
pathways [2]. After synthesis, BAs are transported to and
stored in the gallbladder. BAs are secreted into the small
intestine in response to dietary intake and function to emul-
sify and facilitate the absorption of dietary lipids and fat-
soluble vitamins. However, approximately 95% of BAs are
reabsorbed and transported back to the liver from the ileum,
the distal part of the small intestine. This system is known
as enterohepatic circulation, which provides a relatively
constant pool of BAs. The levels of BAs need to be tightly
regulated, to control not only cholesterol levels but also the
potential toxic eﬀects of BAs when they reach abnormal
levels. For example, both genetic diseases and liver toxins
may induce higher levels of BAs in the liver, thereby resulting
in a liver disease known as cholestasis [3].
It is now clear that, in addition to their important roles
in nutritional absorption, BAs are signaling molecules that
can activate BA receptors to initiate signaling pathways and
regulate gene expression. Two major receptors for BAs have
been identiﬁed: (1) the nuclear receptor, FXR, and (2) the
G protein-coupled receptor (TGR5). FXR is a member of
the nuclear hormone receptor superfamily. Among the 48
currentlyidentiﬁednuclearhormonereceptors,FXRbelongs
to a subcluster of nuclear receptors that play key roles in
metabolic regulation [4]. These receptors work as sensors
of metabolic signals and regulate metabolism by changing
the expression proﬁles of essential components in speciﬁc
metabolic pathways. FXR was ﬁrst cloned in 1995 [5] and is
highly expressed in the liver, intestine, kidney, and adrenal
glands. There is now a large body of evidence indicating
that a critical function of FXR is to control BA homeostasis
in order to prevent BA-induced liver toxicity [6–10]. FXR
regulates BA levels by adjusting the expression of a program
of essential gene components that are involved in BA2 Experimental Diabetes Research
Table 1: Comparison between two BA receptors in liver.
Receptor FXR TGR5
Ligands∗ CDCA > LCA, DCA >
CA





















∗CDCA: chenodeoxycholic acid; CA: cholic acid; DCA: deoxycholic acid;
LCA: lithocholic acid; LPS: lipopolysaccharide.
synthesis, transportation, conjugation, and detoxiﬁcation in
the route of the enterohepatic circulation of BAs [11–
13]. FXR is also an important mediator of BA signaling
and regulates diverse physiological functions. For example,
activation of FXR induces the expression of genes involved in
enteroprotection [14, 15]. Our group and others have iden-
tiﬁed novel functions of FXR in liver regeneration, hepatic
inﬂammation, and hepatocarcinogenesis [16–19].
2.TGR5andBile AcidMetabolism
TGR5 is a recently identiﬁed plasma membrane-bound,
G protein-coupled receptor for BAs. TGR5 is encoded by
a single exon that maps to chromosome 1C3 in mouse and
2q35 in humans. Homologs of TGR5 can also be identiﬁed
in aquatic vertebrates, indicating a potentially conserved role
of TGR5 during evolution. TGR5 is ubiquitously expressed,
but its expression levels vary among diﬀerent tissues, with
high expression in liver, intestine, brown adipose tissue, and
spleen [20, 21]. In vitro studies have demonstrated that
activation of TGR5 transduces signal through Gs protein-
mediated cAMP accumulation [22]. The order of potency
of diﬀerent BAs on TGR5 activation is diﬀerent from FXR,
indicating that these two receptors may have diﬀerential
functions in mediating the eﬀects of BAs (Table 1).
The role of TGR5 in bile acid metabolism was conﬁrmed
in TGR5 knockout mice. Total BA pool size in TGR5 knock-
out mice was signiﬁcantly decreased by 21–25% compared
with that of the wild-type mice, suggesting that TGR5
contributes to BA homeostasis [20]. However, the exact
function of TGR5 and the downstream pathways of TGR5
in regulating BA levels are still unclear. Interestingly, TGR5
activationincreasedtheexpressionofendothelialnitricoxide
synthase(eNOS)[23],whichmaylimithepatotoxicityofBAs
as well as lipid peroxidation. This result suggests that, similar
to FXR, TGR5 may have liver protection function.
Another interesting study indicating a potential role of
TGR5 in BA metabolism is its function in gallstone forma-
tion. TGR5 knock-out mice did not develop gallstones when
they were fed a lithogenic diet [24]. Furthermore, TGR5 was
highly expressed in human gallbladder epithelium at both
the mRNA and protein levels, and the mRNA levels of TGR5
were signiﬁcantly elevated in the presence of gallstones.
TGR5maypromotegallstoneformationthroughstimulating
chloride and ﬂuid secretion in gallbladder epithelial cells in
response to BAs [25] .R e c e n t l y ,T G R 5w a sf o u n dt ol o c a l i z e
in mouse and human primary cilium of cholangiocytes,
indicating a potential role of TGR5 in the biliary diseases
[26]. This was further conﬁrmed by a report that TGR5
appeared to be a likely disease gene in the ﬁrst genome-
wide association analysis of primary sclerosing cholangitis
(PSC) [27]. A potential role of TGR5 in this disease is that
TGR5 may aﬀect cAMP-dependent cholangiocellular HCO3
umbrella [28]. In addition, arginine vasopressin (AVP) has
been suggested to play a role in bile homeostasis [29]. TGR5
was reported to partially stimulate AVP secretion after two-
thirds partial hepatectomy and bile duct ligation, therefore
may protect the liver against shear stress and BA overload
[26, 30].
In summary, BAs mainly signal through two receptors,
FXR and TGR5. FXR is key to controlling the homeostasis of
BAs and preventing the toxic eﬀects of BAs on hepatocytes.
In contrast, TGR5 may establish a secondary and backup
pathway for maintaining BA levels and for preventing BA-
induced toxicity.
3. TGR5 andInﬂammation
TGR5 mRNA was detected in the resting CD14+ mono-
cytes in fractionated human leukocytes, adherent alveolar
macrophage cells [31], and Kupﬀer cells in liver, indicating
a potential role of TGR5 in modulating inﬂammation. Acti-
vation of TGR5 in Kupﬀer cells [32] and THP-1 cells over-
expressingTGR5[31]suppressedlipopolysaccharide-(LPS-)
induced productions of cytokines, suggesting that TGR5
is a mediator in the suppression of macrophage functions
by BAs. Treatment of oleanolic acid (OA), a speciﬁc and
potent TGR5 agonist, before or at the early onset of multiple
sclerosis animal model, ameliorated neurological signs of the
disease, indicating that TGR5 modulates inﬂammation and
immune responses in vivo [33]. Previously, we demonstrated
that FXR antagonizes NF-κB-mediated hepatic inﬂamma-
tion [19]. Whether TGR5 plays a similar role in suppress-
ing NF-κB function during hepatic inﬂammation will be
an interesting future study.
4.TGR5 andGlucose Metabolism
TGR5 may play a potential role in type 2 diabetes, as sug-
gested by a recent ﬁnding that OA treatment lowered serum
glucose and insulin levels in mice fed with a high-fat diet.
Moreover, OA treatment enhanced glucose tolerance [34].
Activation of TGR5 induced the production of glucagon-
like peptide-1 (GLP-1) in an enteroendocrine cell line STC-1
[35], which was further conﬁrmed by a recent report using
TGR5 overexpression mice. The authors showed that TGR5-
induced intestinal GLP-1 release led to improved function of
liver and pancreas and enhanced glucose tolerance in obese
mice [36] .H o w e v e r ,ar e c e n ts t u d ys u g g e s t e dt h a tc o m m o n
genetic variation within the TGR5 gene might not playExperimental Diabetes Research 3
a major role in the development of prediabetic phenotypes
in white population at an increased risk for type 2 diabetes
mellitus [37]. Therefore, the exact role of TGR5 in glucose
metabolism requires more investigation.
5.TGR5andEnergyMetabolism
Overweight and obesity are now viewed as chronic diseases
in the whole world that threaten public health if not
treated [38]. Obesity is the result from imbalance of energy
metabolism, in which the energy intake exceeds energy
expenditure. It is now known that two types of adipose
tissuesplayoppositeroles:whiteadiposetissue(WAT) stores
energy in the form of lipid and brown adipose tissue
(BAT) dissipates energy as heat by thermogenesis [39]. The
selection of BAT as a site for energy dissipation is because
it contains much higher number of mitochondria compared
to other tissues. Moreover, the expression of a protein called
uncoupling protein 1 (UCP1, thermogenin) in the inner
membrane of mitochondria in BAT is high, and this protein
is able to help generate heat instead of ATP in mitochondria.
The critical role of BAT in energy burning is becoming
more and more recognized in rodent models and recently in
human also. Three reports published back to back in New
England Journal of Medicine demonstrate that adult humans
have signiﬁcant amount of metabolically active BAT [40–
42]. Is it possible to manipulate BAT to combat obesity?
One way for this purpose is to increase the amount of
BAT. Endogenous signals and transcription factors are being
identiﬁed that control BAT diﬀerentiation and development
[43–45]. Another possibility is to simply transplant BAT.
However, both approaches need more studies and it may
take longer to develop a technique to increase BAT volume.
Another concern will be the potential long-term deleterious
eﬀect when you expand the BAT but cannot remove it easily.
An alternative way to burn energy is to increase the activity
of BAT. Thus, TGR5 ligands are potential drug candidates for
this purpose.
TGR5 is a key factor in energy expenditure by regulating
metabolism. Activation of TGR5 by BAs increases energy
expenditure in brown adipose tissue, preventing obesity and
resistance to insulin [46]. This eﬀect is FXR-independent
but TGR5-dependent. TGR5 mediates the induction of the
cyclic-AMP-dependent thyroid hormone activating enzyme
type 2 iodothyronine deiodinase (D2), which is essential for
the eﬀect of BAs. BAs preferentially induce D2 expression in
thermogenical tissues of mouse brown fat and human skele-
tal muscle via a TGR5-dependent manner. D2 subsequently
converts thyroxine (T4) to tri-iodothyronine (T3). T3 is
predicted to induce uncoupling protein (UCP) expression.
UCP is known to dissipate the proton gradient in the
electron transport chain. Therefore, the activation of BAs/
TGR5/cyclic AMP/D2/T3/UCP pathway causes a decrease in
the synthesis of ATP and thus regulates energy homeostasis.
A further study on the responses of TGR5 null mice to high-
fat diet in part supports this notion. Female TGR5 –/– mice
on a high-fat diet gained more body weight than wild-type
mice [20].
Table 2: List of currently available synthetic TGR5 ligands.














An interesting question is whether activation of TGR5
by natural or synthetic ligands would reduce body weight
caused by the high-fat diet. Oleanolic acid (OA), a natural
ligand of TGR5 isolated from Olea europaea, indeed abol-
ished the gain of the body weight by the high-fat diet in an
animal model [34]. It improved the glucose tolerance and
metabolic disorders as well. However, whether the eﬀects of
OA are TGR5-dependent still needs to be determined. Nev-
ertheless, the results highlight a potential use of TGR5 ago-
nists in the antidiabetic or antiobesity studies.
Besides OA, several other types of secondary BAs are also
natural ligands for TGR5, for example LCA, TLCA, DCA,
CDCA, and CA [47]. However, these ligands are either toxic
or not suﬃciently safe. Among them, CDCA appears to be
a promising ligand and has been applied in clinical practice
[48]. Thyroid hormone treatment for weight loss is known
to cause side eﬀects in both urinary nitrogen excretion and
heart rates, which are not seen in patients treated with BAs
[42, 49]. However, a higher dose of CDCA will elevate serum
levels of AST and ALT in patients due to liver damage. In
this sense, development of natural or semisynthetic TGR5
ligands may be a future direction for clinical trials. One
group of the synthetic TGR5 ligands is the semisynthetic
steroidal TGR5 agonists, for example 6EMCA, which is a de-
rivative of CDCA. The second groups are the synthetic
nonsteroidal TGR5 agonists, which may improve metabolic
homeostasis,pancreaticinsulinsecretion,andinﬂammation.
The synthetic ligands are summarized in the Table 2 [21, 36,
47,50,51].Inaddition,discoveryofnewnaturalcompounds
as TGR5 agonists would be also a promising future direction.
6. Concluding Remarks
TGR5 is an emerging membrane receptor for mediating bile
acid signaling. Recent studies highlight it as a novel target
for regulating glucose and energy metabolism. The TGR5
signaling in BAT and muscle, two important sites of energy
dissipation, suggests that it may be a novel target to combat
obesity. We anticipate that, in the near future, more potent4 Experimental Diabetes Research
and speciﬁc TGR5 ligands will be identiﬁed and go into
clinical trials for obesity and diabetes treatments.
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